The inhibitors used today workon the principle of synthetic lethality to destroy cancer cellswith defects in the homologous recombination system (forexample, with BRCA1/2 mutations), converting single-strandDNA breaks into double-strand breaks that cannot be effectivelyrepaired, leading to cancer cell death. Here, BRCA1 is linked to cancer.